Tagged with GEN

Turkey As one of the leading pharma companies in Turkey, DEVA is pioneering a new approach to generics in the country. Chairman of the Board and CEO Philipp Haas discusses the company’s presence and strategy in international markets, how the firm is leveraging its three US FDA-approved and EU GMP-certified production…

USA Taking the example of music’s effect on Alzheimer’s disease patients, John G Singer makes the case for a more holistic approach to healthcare; focusing less on the transformative potential of individual drugs and more on value as a stream of benefits delivered through a living system.   Singer/songwriter Glen Campbell,…

Singapore Annie Tan highlights the strategy she laid out to navigate the BMS Singapore, Thailand and Malaysia affiliates through the COVID-19 pandemic; the opportunities and challenges of integrating the Celgene portfolio into local BMS operations; and her aim to build the company into an oncology and haematology powerhouse in Southeast Asia…

Switzerland The Novartis and Roche names are synonymous with Swiss pharmaceutical innovation. But for these two Basel-based global behemoths, what value does Switzerland itself hold and what do they see as the areas in which they can truly bring value in their home market?   Roche – Driving Digital & Personalised…

Global Merck VP for Global Market Access & Pricing Strategic Planning Marco Rauland outlines how AI has already begun to transform pharmaceutical strategy and highlights five ways in which it can be better utilised in pricing and market access decision making.   Artificial intelligence (AI) has been creating a buzz in…

India The latest from Indian pharma, including the year-to-year 51.5 percent growth of the pharma market in April, Lilly’s partnership with three generics makers to expand the availability of its arthritis drug baricitinib, Zydus Cadila’s upcoming approval of its COVID-19 vaccine, and the emergency use authorization for a COVID-19 antibody drug…

Asia-Pacific Generics penetration in the Asia-Pacific region by country for 2018. A full 90.3 percent of all medicines dispensed in India were generics compared to 78.3 percent in China and 76.9 percent in Indonesia. At the other end of the scale, Japan and Taiwan had a generics penetration of just 28.9…

MEA Mohamed Nasser, Amgen’s general manager for the vast Middle East & Africa (MEA) region, leverages his considerable experience managing teams across the region to highlight four skills (and one secret ingredient) that pharma country and regional managers in MEA need to succeed.   The Middle East-Africa area (MEA) is one…

Asia-Pacific Asia-Pacific, as home to 50 percent of the world’s new cancer cases each year and with deaths caused by cancer expected to increase by 36 percent by 2030, has a pressing need for more patient-centric, data-driven, value-based, and precise solutions in oncology. Additionally, Asian cancer patients’ healthcare needs can differ…

Singapore Lucas Chan, Scientific Founder and CSO of CellVec, a Singapore-based CDMO that specializes in the development and manufacture of viral vectors for clinical gene therapy, discusses how his company is helping companies with mature preclinical gene therapy projects wanting to progress into the clinic. Moreover, he discusses why Singapore is…

China Genetron Health is a publicly-traded China-based precision oncology company, covering the “full-cycle” of cancer care, from early screening, diagnosis, and treatment recommendations to continuous monitoring care. CEO and Co-Founder Sizhen Wang explains how the company obtained US FDA Breakthrough Device Designation, analyzes the Chinese biotech sector, and highlights their objective…

Switzerland Vincent Gruntz looks at the market dynamics for oncology in Switzerland, where an increasingly cost-conscious approach is being taken to reimbursement and pricing, his experience of bringing CAR-T therapies to the country, and the challenges and opportunities of ‘virtual’ product launches.   Once you have seen a patient – that…